The Gene Panel Market study analyzes and forecasts the market size across 6 regions and 24 countries for diverse segments- By Products and Services (Test kits, Testing services), By Technique (Amplicon based approach, Hybridization based approach), By Design (Predesigned, Customized).
Gene panels, also known as gene panels or genetic panels, are targeted sequencing assays that simultaneously analyze multiple genes associated with a particular disease or phenotype. In 2024, gene panels continue to revolutionize genetic testing and personalized medicine, offering comprehensive and cost-effective solutions for the diagnosis, risk assessment, and treatment selection for a wide range of genetic disorders, cancer types, and complex diseases. These panels typically focus on genes known to be involved in specific pathways or conditions, such as cancer susceptibility, cardiovascular disease risk, or inherited genetic disorders. By sequencing multiple genes in a single test, gene panels provide clinicians with valuable information about an individual's genetic makeup, enabling personalized risk assessment, early detection of disease, and tailored treatment strategies. Moreover, with advancements in next-generation sequencing (NGS) technologies, bioinformatics analysis, and variant interpretation algorithms, gene panels offer improved sensitivity, specificity, and scalability, allowing for rapid and accurate genetic testing in clinical settings. By facilitating timely diagnosis, prognostication, and therapeutic decision-making, gene panels contribute to improved patient outcomes, reduced healthcare costs, and enhanced precision in medical care, ultimately revolutionizing the practice of genomic medicine and transforming the landscape of healthcare delivery.
A significant trend in the gene panel market is the shift towards personalized medicine and precision oncology. With advancements in genomic sequencing technologies and bioinformatics, there is a growing emphasis on utilizing gene panels to tailor cancer treatment strategies to individual patients based on their unique genetic profiles. Gene panels allow for the simultaneous analysis of multiple genes associated with cancer susceptibility, tumor progression, and drug response, enabling oncologists to identify actionable mutations and select targeted therapies with higher efficacy and fewer adverse effects. This trend is driven by the increasing recognition of the heterogeneity of cancer and the need for more precise and personalized treatment approaches to improve patient outcomes. As healthcare systems prioritize value-based care and molecularly-guided therapies, the demand for gene panel testing in oncology is expected to grow, driving market expansion and innovation in genomic diagnostics.
A key driver fueling the gene panel market is the rising incidence of cancer worldwide and the growing demand for comprehensive molecular profiling in oncology practice. Cancer remains a leading cause of morbidity and mortality globally, with millions of new cases diagnosed each year. Comprehensive molecular profiling using gene panels enables oncologists to identify genetic alterations driving tumor growth, metastasis, and treatment resistance, thereby guiding treatment decisions and optimizing patient outcomes. The increasing availability of targeted therapies and immunotherapies, coupled with the need for biomarker-driven clinical trials, underscores the importance of accurate and comprehensive genomic testing in cancer care. As the landscape of cancer treatment evolves towards more personalized and targeted approaches, the demand for gene panel testing as a component of precision oncology is expected to grow, driving market growth and adoption of genomic diagnostic technologies.
A potential opportunity in the gene panel market lies in the integration of artificial intelligence (AI) and machine learning (ML) algorithms into genomic data analysis pipelines. AI and ML technologies have the potential to enhance the interpretation of complex genomic data generated from gene panel testing, enabling more accurate variant classification, pathway analysis, and prediction of treatment response. By leveraging AI-driven algorithms, bioinformatics platforms can automate variant annotation, prioritize clinically-relevant mutations, and provide actionable insights to healthcare providers in real-time. Additionally, AI-powered decision support systems can assist oncologists in selecting optimal treatment strategies based on the patient's genetic profile and clinical characteristics. By investing in AI and ML capabilities, gene panel testing providers can offer more sophisticated and clinically meaningful genomic solutions, differentiate their services in the market, and improve patient care outcomes. Expanding into AI-driven genomic analysis presents a strategic opportunity for gene panel testing companies to drive innovation, enhance diagnostic accuracy, and capture a larger share of the growing precision medicine market.
Within the gene panel market, the segment witnessing the most rapid growth is the amplicon-based approach. This surge in demand can be attributed to several factors. Amplicon-based gene panels offer several advantages, including high sensitivity, specificity, and cost-effectiveness, making them increasingly preferred for targeted genetic analysis. Moreover, advancements in next-generation sequencing (NGS) technologies have enhanced the efficiency and throughput of amplicon-based assays, enabling comprehensive analysis of multiple genes in a single assay. Additionally, the growing adoption of precision medicine and personalized healthcare drives the demand for customized gene panels tailored to specific research or clinical objectives. These factors collectively contribute to the rapid growth of the amplicon-based approach within the gene panel market, positioning it as the fastest-growing segment in the industry.
The market research study provides in-depth insights into leading companies including the SWOT analyses, product profile, financial details, and recent developments acrossAgilent Technologies Inc, Bio-Rad Laboratories Inc, Cepheid Inc, Eurofins Genomics LLC, Foundation Medicine Inc, Guardant Health Inc, Illumina Inc, Myriad Genetics Inc, Personalis Inc, QIAGEN N.V., Thermo Fisher Scientific Inc
By Products and Services
Test kits
Testing services
By Technique
Amplicon based approach
Hybridization based approach
By Design
Predesigned
Customized
Geographical Analysis
North America (United States, Canada, Mexico)
Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)
Agilent Technologies Inc
Bio-Rad Laboratories Inc
Cepheid Inc
Eurofins Genomics LLC
Foundation Medicine Inc
Guardant Health Inc
Illumina Inc
Myriad Genetics Inc
Personalis Inc
QIAGEN N.V.
Thermo Fisher Scientific Inc
• Deepen your industry insights and navigate uncertainties for strategy formulation, CAPEX, and Operational decisions
• Gain access to detailed insights on the Gene Panel Market, encompassing current market size, growth trends, and forecasts till 2030.
• Access detailed competitor analysis, enabling competitive advantage through a thorough understanding of market players, strategies, and potential differentiation opportunities
• Stay ahead of the curve with insights on technological advancements, innovations, and upcoming trends
• Identify lucrative investment avenues and expansion opportunities within the Gene Panel Market industry, guided by robust, data-backed analysis.
• Understand regional and global markets through country-wise analysis, regional market potential, regulatory nuances, and dynamics
• Execute strategies with confidence and speed through information, analytics, and insights on the industry value chain
• Corporate leaders, strategists, financial experts, shareholders, asset managers, and governmental representatives can make long-term planning scenarios and build an integrated and timely understanding of market dynamics
• Benefit from tailored solutions and expert consultation based on report insights, providing personalized strategies aligned with specific business needs.
TABLE OF CONTENTS
1 Introduction to 2024 Gene Panel Market
1.1 Market Overview
1.2 Quick Facts
1.3 Scope/Objective of the Study
1.4 Market Definition
1.5 Countries and Regions Covered
1.6 Units, Currency, and Conversions
1.7 Industry Value Chain
2 Research Methodology
2.1 Market Size Estimation
2.2 Sources and Research Methodology
2.3 Data Triangulation
2.4 Assumptions and Limitations
3 Executive Summary
3.1 Global Gene Panel Market Size Outlook, $ Million, 2021 to 2030
3.2 Gene Panel Market Outlook by Type, $ Million, 2021 to 2030
3.3 Gene Panel Market Outlook by Product, $ Million, 2021 to 2030
3.4 Gene Panel Market Outlook by Application, $ Million, 2021 to 2030
3.5 Gene Panel Market Outlook by Key Countries, $ Million, 2021 to 2030
4 Market Dynamics
4.1 Key Driving Forces of Gene Panel Industry
4.2 Key Market Trends in Gene Panel Industry
4.3 Potential Opportunities in Gene Panel Industry
4.4 Key Challenges in Gene Panel Industry
5 Market Factor Analysis
5.1 Value Chain Analysis
5.2 Competitive Landscape
5.2.1 Global Gene Panel Market Share by Company (%), 2023
5.2.2 Product Offerings by Company
5.3 Porter’s Five Forces Analysis
5.4 Pricing Analysis and Outlook
6 Growth Outlook Across Scenarios
6.1 Growth Analysis-Case Scenario Definitions
6.2 Low Growth Scenario Forecasts
6.3 Reference Growth Scenario Forecasts
6.4 High Growth Scenario Forecasts
7 Global Gene Panel Market Outlook by Segments
7.1 Gene Panel Market Outlook by Segments, $ Million, 2021- 2030
By Products and Services
Test kits
Testing services
By Technique
Amplicon based approach
Hybridization based approach
By Design
Predesigned
Customized
8 North America Gene Panel Market Analysis and Outlook To 2030
8.1 Introduction to North America Gene Panel Markets in 2024
8.2 North America Gene Panel Market Size Outlook by Country, 2021-2030
8.2.1 United States
8.2.2 Canada
8.2.3 Mexico
8.3 North America Gene Panel Market size Outlook by Segments, 2021-2030
By Products and Services
Test kits
Testing services
By Technique
Amplicon based approach
Hybridization based approach
By Design
Predesigned
Customized
9 Europe Gene Panel Market Analysis and Outlook To 2030
9.1 Introduction to Europe Gene Panel Markets in 2024
9.2 Europe Gene Panel Market Size Outlook by Country, 2021-2030
9.2.1 Germany
9.2.2 France
9.2.3 Spain
9.2.4 United Kingdom
9.2.4 Italy
9.2.5 Russia
9.2.6 Norway
9.2.7 Rest of Europe
9.3 Europe Gene Panel Market Size Outlook by Segments, 2021-2030
By Products and Services
Test kits
Testing services
By Technique
Amplicon based approach
Hybridization based approach
By Design
Predesigned
Customized
10 Asia Pacific Gene Panel Market Analysis and Outlook To 2030
10.1 Introduction to Asia Pacific Gene Panel Markets in 2024
10.2 Asia Pacific Gene Panel Market Size Outlook by Country, 2021-2030
10.2.1 China
10.2.2 India
10.2.3 Japan
10.2.4 South Korea
10.2.5 Indonesia
10.2.6 Malaysia
10.2.7 Australia
10.2.8 Rest of Asia Pacific
10.3 Asia Pacific Gene Panel Market size Outlook by Segments, 2021-2030
By Products and Services
Test kits
Testing services
By Technique
Amplicon based approach
Hybridization based approach
By Design
Predesigned
Customized
11 South America Gene Panel Market Analysis and Outlook To 2030
11.1 Introduction to South America Gene Panel Markets in 2024
11.2 South America Gene Panel Market Size Outlook by Country, 2021-2030
11.2.1 Brazil
11.2.2 Argentina
11.2.3 Rest of South America
11.3 South America Gene Panel Market size Outlook by Segments, 2021-2030
By Products and Services
Test kits
Testing services
By Technique
Amplicon based approach
Hybridization based approach
By Design
Predesigned
Customized
12 Middle East and Africa Gene Panel Market Analysis and Outlook To 2030
12.1 Introduction to Middle East and Africa Gene Panel Markets in 2024
12.2 Middle East and Africa Gene Panel Market Size Outlook by Country, 2021-2030
12.2.1 Saudi Arabia
12.2.2 UAE
12.2.3 Oman
12.2.4 Rest of Middle East
12.2.5 Egypt
12.2.6 Nigeria
12.2.7 South Africa
12.2.8 Rest of Africa
12.3 Middle East and Africa Gene Panel Market size Outlook by Segments, 2021-2030
By Products and Services
Test kits
Testing services
By Technique
Amplicon based approach
Hybridization based approach
By Design
Predesigned
Customized
13 Company Profiles
13.1 Company Snapshot
13.2 SWOT Profiles
13.3 Products and Services
13.4 Recent Developments
13.5 Financial Profile
List of Companies
Agilent Technologies Inc
Bio-Rad Laboratories Inc
Cepheid Inc
Eurofins Genomics LLC
Foundation Medicine Inc
Guardant Health Inc
Illumina Inc
Myriad Genetics Inc
Personalis Inc
QIAGEN N.V.
Thermo Fisher Scientific Inc
14 Appendix
14.1 Customization Offerings
14.2 Subscription Services
14.3 Related Reports
14.4 Publisher Expertise
By Products and Services
Test kits
Testing services
By Technique
Amplicon based approach
Hybridization based approach
By Design
Predesigned
Customized
Countries Analyzed
North America (United States, Canada, Mexico)
Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)
The global Gene Panel Market is one of the lucrative growth markets, poised to register a 17.2% growth (CAGR) between 2024 and 2030.
Emerging Markets across Asia Pacific, Europe, and Americas present robust growth prospects.
Agilent Technologies Inc, Bio-Rad Laboratories Inc, Cepheid Inc, Eurofins Genomics LLC, Foundation Medicine Inc, Guardant Health Inc, Illumina Inc, Myriad Genetics Inc, Personalis Inc, QIAGEN N.V., Thermo Fisher Scientific Inc
Base Year- 2023; Estimated Year- 2024; Historic Period- 2018-2023; Forecast period- 2024 to 2030; Currency: USD; Volume